Foghorn Therapeutics Inc. FHTX
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Foghorn Therapeutics Inc. (FHTX) is a healthcare company listed in the US with a market value of about $124M. In the twelve months to September 30, 2026 it had revenue of $112M and net income of $9M, a net margin of 8.4%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 16.0, 5-year revenue growth of 135% a year, a 5-year average ROIC of -139%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 95% below the current price.
About Foghorn Therapeutics
Foghorn Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $430000 in 2020 to $31M in 2025, growth of about 135.1% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 51% over three years (dilution for shareholders). It spends 277% of revenue on research and development.
Score: 1.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- Positive free cash flow
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $112M | $31M | $23M | $34M | $19M | $1M | $430000 | — |
| Net income | $9M | -$74M | -$87M | -$98M | -$109M | -$101M | -$69M | -$51M |
| Free cash flow | -$84M | -$86M | -$101M | -$119M | $192M | -$54M | -$47M | -$47M |
| EPS (diluted) | $0.13 | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 | $-6.23 | $-12.20 |
| Net margin | 8.4% | -240.3% | -383.2% | -288.2% | -566.3% | -7681.6% | -16000.0% | — |
| ROIC | — | — | — | — | -226.9% | -51.3% | -23.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Foghorn Therapeutics’s P/E ratio?
About 16.0, based on the last twelve months of diluted earnings per share.
Is Foghorn Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 95% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Foghorn Therapeutics pay a dividend?
Not currently.
Is Foghorn Therapeutics a good stock to buy?
We do not give buy or sell advice. Foghorn Therapeutics scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.